Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing

Blood

Volumn 117, Issue 3, 2011, Pages 915-919

  Feldman, Andrew L ^a   Dogan, Ahmet ^a   Smith, David I ^a   Law, Mark E ^a   Ansell, Stephen M ^a   Johnson, Sarah H ^a   Porcher, Julie C ^a   Özsan, Nazan ^b   Wieben, Eric D ^a   Eckloff, Bruce W ^a   Vasmatzis, George ^a  

^a MAYO CLINIC   (United States)

^b EGE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ADULT; AGED; ARTICLE; CHROMOSOME FRAGILE SITE; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; UPREGULATION;

EID: 78751692894     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-303305     Document Type: Article

References (25)

1. Rowley JD. Chromosomal translocations: revisited yet again. Blood. 2008;112(6):2183-2189.
2. Swerdlow S, Campo E, Harris N, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
3. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913-3921. (Pubitemid 29249840)
4. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev. 2008;28(3):372-412. (Pubitemid 351590540)
5. Mason DY, Harris NL, Delsol G, et al. Anaplastic large cell lymphoma, ALK-negative. In: Swerdlow S, Campo E, Harris N, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008:317-319.
6. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23(3):574-580.
7. Vasmatzis G, Klee EW, Kube DM, Therneau TM, Kosari F. Quantitating tissue specificity of human genes to facilitate biomarker discovery. Bioinformatics. 2007;23(11):1348-1355. (Pubitemid 47050516)
8. Wada D, Law M, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies [published online ahead of print December 17, 2010]. Mod Pathol. doi:10.1038/modpathol.2010.225.
9. Ralfkiaer E, Willemze R, Paulli M, Kadin ME. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow S, Campo E, Harris N, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
10. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496-5504.
11. Alonso A, Merlo JJ, Na S, et al. Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR). J Biol Chem. 2002;277(7):5524-5528. (Pubitemid 34968603)
12. Sekine Y, Ikeda O, Hayakawa Y, et al. DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118. Oncogene. 2007;26(41):6038-6049. (Pubitemid 47373806)
13. Jantus Lewintre E, Reinoso Martin C, Montaner D, et al. Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups. Leuk Lymphoma. 2009;50(1):68-79.
14. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptor- type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006;108(10):3428-3433.
15. Kleppe M, Lahortiga I, El Chaar T, et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42(6):530-535.
16. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic largecell lymphoma. Blood. 2006;108(8):2796-2803.
17. Arlt MF, Durkin SG, Ragland RL, Glover TW. Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst). 2006;5(9):1126-1135. (Pubitemid 44376448)
18. Murnane JP. Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res. 2010;70(11):4255-4259.
19. Schneider B, Nagel S, Kaufmann M, et al. T(3;7)(q27;q32) fuses BCL6 to a non-coding region at FRA7H near miR-29. Leukemia. 2008;22(6):1262-1266.
20. Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martinez P, Piris MA. MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia. 2007;21(12):2547-2549. (Pubitemid 350148903)
21. Narducci MG, Pescarmona E, Lazzeri C, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 2000;60(8):2095-2100. (Pubitemid 30225165)
22. Han YC, Park CY, Bhagat G, et al. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med.207(3):475-489.
23. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep. 2009;10(4):400-405.
24. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature. 2009;458(7234):97-101.
25. Karenko L, Hahtola S, Paivinen S, et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res. 2005;65(18):8101-8110. (Pubitemid 41330572)